• The Future of Allergy Treatment 1010

    The Future of Allergy Treatment

    Ultra-Fast Allergy Immunotherapy with Long Contiguous Overlapping Peptides

  • The Future of Allergy Treatment

    The Future of Allergy Treatment

    Long-Lasting Allergy Symptom Relief after a Single Two-Month Treatment Course

  • The Future of Allergy Treatment

    The Future of Allergy Treatment

    Proprietary Technology Platform to Defeat Allergies

  • The Future of Allergy Treatment

    The Future of Allergy Treatment

    Dedicated to Research and Development in Allergy Immunotherapy


million patients suffering from allergies worldwide

years of peptide and immunology research

months of single pre-seasonal treatment course

patients treated in ultra-fast AIT clinical trials

% of patients satisfied after allergy season

years of documented specific immune memory

Kettner A, DellaCorte G, de Blay F, Jacobsen L, Jutel M, Worm M, Charlon V, Simonsen K, Reymond C, Spertini F. Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season. J Allergy Clin Immunol 2018; 142:678-80 e7.

Pfaar O, Bonini S, Cardona V, Demoly P, Jakob T, Jutel M, Kleine-Tebbe J, Klimek L, Klysner S, Kopp MV, Kuna P, Larche M, Muraro A, Schmidt-Weber CB, Shamji MH, Simonsen K, Somoza C, Valovirta E, Zieglmayer P, Zuberbier T, Wahn U; FASIT group. Perspectives in allergen immunotherapy: 2017 and beyond. Allergy 2018;73 Suppl 104:5-23.

Hoffmann HJ, Valovirta E, Pfaar O, Moingeon P, Schmid JM, Skaarup SH, Cardell LO, Simonsen K, Larche M, Durham SR, Sorensen P. Novel approaches and perspectives in allergen immunotherapy. Allergy 2017;72(7):1022-34.

Spertini F, DellaCorte G, Kettner A, de Blay F, Jacobsen L, Jutel M, Worm M, Charlon V, Reymond C. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study. J Allergy Clin Immunol 2016; 138:162-8.

Spertini F, Perrin Y, Audran R, Pellaton C, Boudousquie C, Barbier N, Thierry AC, Charlon V, Reymond C. Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides. J Allergy Clin Immunol 2014; 134:239-40 e13.

Pellaton C, Perrin Y, Boudousquie C, Barbier N, Wassenberg J, Corradin G, Thierry AC, Audran R, Reymond C, Spertini F. Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin Transl Allergy 2013; 3:17.

Spertini F, Reymond C, Leimgruber A. Allergen-specific immunotherapy of allergy and asthma: current and future trends. Expert Rev Respir Med 2009; 3:37-51.

Fellrath JM, Kettner A, Dufour N, Frigerio C, Schneeberger D, Leimgruber A, Corradin G, Spertini F. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003; 111:854-61.

Jilek S, Barbey C, Spertini F, Corthesy B. Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. J Immunol 2001; 166:3612-21.

von Garnier C, Astori M, Kettner A, Dufour N, Heusser C, Corradin G, Spertini F. Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis. Eur J Immunol 2000; 30:1638-45.

Astori M, von Garnier C, Kettner A, Dufour N, Corradin G, Spertini F. Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice. J Immunol 2000; 165:3497-505.

Kammerer R, Kettner A, Chvatchko Y, Dufour N, Tiercy JM, Corradin G, Spertini F. Delineation of PLA2 epitopes using short or long overlapping synthetic peptides: interest for specific immunotherapy. Clin Exp Allergy 1997; 27:1016-26.

Kammerer R, Chvatchko Y, Kettner A, Dufour N, Corradin G, Spertini F. Modulation of T-cell response to phospholipase A2 and phospholipase A2-derived peptides by conventional bee venom immunotherapy. J Allergy Clin Immunol 1997; 100:96-103.


  • Biopôle Building SC-A
    Route de la Corniche 4
    CH-1066 Epalinges
  • Email:

This website uses cookies to ensure you get the best experience on our website.